JP5393798B2 - リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム - Google Patents

リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム Download PDF

Info

Publication number
JP5393798B2
JP5393798B2 JP2011532094A JP2011532094A JP5393798B2 JP 5393798 B2 JP5393798 B2 JP 5393798B2 JP 2011532094 A JP2011532094 A JP 2011532094A JP 2011532094 A JP2011532094 A JP 2011532094A JP 5393798 B2 JP5393798 B2 JP 5393798B2
Authority
JP
Japan
Prior art keywords
lipoprotein
insulin resistance
risk
score
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011532094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506051A5 (enExample
JP2012506051A (ja
Inventor
オトヴォス，ジェイムズ・ディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liposcience Inc
Original Assignee
Liposcience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposcience Inc filed Critical Liposcience Inc
Publication of JP2012506051A publication Critical patent/JP2012506051A/ja
Publication of JP2012506051A5 publication Critical patent/JP2012506051A5/ja
Application granted granted Critical
Publication of JP5393798B2 publication Critical patent/JP5393798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011532094A 2008-10-20 2009-10-20 リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム Active JP5393798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10683308P 2008-10-20 2008-10-20
US61/106,833 2008-10-20
PCT/US2009/005689 WO2010047767A2 (en) 2008-10-20 2009-10-20 Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same

Publications (3)

Publication Number Publication Date
JP2012506051A JP2012506051A (ja) 2012-03-08
JP2012506051A5 JP2012506051A5 (enExample) 2012-12-06
JP5393798B2 true JP5393798B2 (ja) 2014-01-22

Family

ID=42109358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532094A Active JP5393798B2 (ja) 2008-10-20 2009-10-20 リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム

Country Status (7)

Country Link
US (1) US8386187B2 (enExample)
EP (2) EP4016105A1 (enExample)
JP (1) JP5393798B2 (enExample)
KR (1) KR20110086074A (enExample)
AU (1) AU2009308124B2 (enExample)
CA (1) CA2741034C (enExample)
WO (1) WO2010047767A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010047767A2 (en) 2008-10-20 2010-04-29 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
WO2013003454A2 (en) * 2011-06-30 2013-01-03 Liposcience, Inc. Quantitative nmr clinical analyzers with automatic nmr temperature sensitivity compensation that accommodate large ambient operational temperature ranges
JP6308954B2 (ja) * 2012-03-05 2018-04-11 オサケユキテュア・アークティック・パートナーズ・アクチボラゲットＯｙ Ａｒｃｔｉｃ Ｐａｒｔｎｅｒｓ Ａｂ 前立腺癌のリスク及び前立腺容積を予測する方法及び装置
US9483611B2 (en) 2012-04-27 2016-11-01 Liposcience, Inc. Protective HDL particle number evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
JP6696907B2 (ja) * 2014-01-06 2020-05-20 リポサイエンス，インコーポレイテッド 糖尿病への転化を予測する多重マーカリスクパラメータ
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
CA2982262A1 (en) 2015-04-29 2016-11-03 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
KR102539142B1 (ko) 2016-09-05 2023-06-01 삼성전자주식회사 스펙트럼 분석 장치와 방법, 및 혈당 측정 장치
US10775458B2 (en) 2018-03-05 2020-09-15 Texas Tech University System Method and system for non-invasive measurement of metabolic health
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
WO2022089749A1 (en) * 2020-10-29 2022-05-05 Telefonaktiebolaget Lm Ericsson (Publ) Checking state consistency in a log replication configuration
CN113117241B (zh) * 2021-04-15 2022-01-28 中国科学院合肥物质科学研究院 一种提高胰岛素水平和敏感性的磁场发生装置及其应用
CN115188493A (zh) * 2022-07-13 2022-10-14 天津市人民医院 一种胰岛素抵抗预测模型的构建系统、方法及应用
WO2024097429A1 (en) * 2022-11-05 2024-05-10 Texas Tech University System Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals
CN120613144B (zh) * 2025-05-27 2026-02-03 中国科学院精密测量科学与技术创新研究院 一种基于血液nmr编辑谱的药物敏感度预测方法
CN120280166A (zh) * 2025-06-10 2025-07-08 南昌大学第二附属医院 术后胰岛素抵抗风险预测模型的构建方法及系统

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933844A (en) 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
AU2384292A (en) 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
US6653140B2 (en) * 1999-02-26 2003-11-25 Liposcience, Inc. Methods for providing personalized lipoprotein-based risk assessments
EP1171778B1 (en) * 1999-04-22 2006-03-01 Liposcience, Inc. Nmr-method for determining the risk of developing type 2 diabetes
US7395158B2 (en) * 2000-05-30 2008-07-01 Sensys Medical, Inc. Method of screening for disorders of glucose metabolism
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US6617167B2 (en) * 2001-08-01 2003-09-09 Liposcience, Inc. Method of determining presence and concentration of lipoprotein X in blood plasma and serum
CA2467420A1 (en) * 2001-11-13 2003-05-22 The Regents Of The University Of California Ion mobility analysis of biological particles
AU2003285926A1 (en) * 2002-10-25 2004-05-25 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
DE10315877B4 (de) * 2003-04-08 2005-11-17 Roche Diagnostics Gmbh Krankheitsverlaufkontrolle
FR2853911B1 (fr) * 2003-04-17 2005-07-08 Merck Sante Sas Gene induit par l'insuline, comme cible therapeutique dans le diabete
CA2539430C (en) * 2003-09-23 2015-03-17 The General Hospital Corporation Screening for gestational disorders with sex hormone binding globulin as biomarker
AU2005230449B2 (en) * 2004-04-01 2010-02-18 Liposcience, Inc. NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
US9372190B2 (en) * 2004-05-26 2016-06-21 Region Nordjylland Method of evaluation of the relative risk of developing atherosclerosis in patients
DE102004026903B4 (de) * 2004-06-01 2006-05-18 Universität Regensburg Verfahren zur Bestimmung von Lipoproteinen in Körperflüssigkeiten und Messanordnung dafür
HUE029170T2 (en) * 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
JP4210855B2 (ja) * 2004-09-28 2009-01-21 大塚製薬株式会社 インスリン抵抗性の評価方法
US7323296B2 (en) * 2004-10-01 2008-01-29 Yuanhong Ma Method and index for diagnosing insulin resistance
EP1645877A1 (en) * 2004-10-08 2006-04-12 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for providing a insulin resistance biomarker profile of one or more lipids
EP1872138A1 (en) * 2005-04-11 2008-01-02 AstraZeneca AB A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes.
WO2007133593A2 (en) * 2006-05-10 2007-11-22 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements
EP2164977B1 (en) * 2007-07-17 2013-10-30 Metabolon, Inc. Biomarkers for pre-diabetes and methods using the same
US20090191576A1 (en) * 2008-01-28 2009-07-30 Yuanhong Ma Method and index for diagnosing insulin resistance
WO2010047767A2 (en) 2008-10-20 2010-04-29 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same

Also Published As

Publication number Publication date
US20100100334A1 (en) 2010-04-22
AU2009308124A1 (en) 2010-04-29
US8386187B2 (en) 2013-02-26
CA2741034C (en) 2021-06-22
EP2344890A2 (en) 2011-07-20
EP2344890A4 (en) 2012-12-26
AU2009308124B2 (en) 2014-12-11
EP2344890B1 (en) 2021-08-11
EP4016105A1 (en) 2022-06-22
WO2010047767A3 (en) 2010-08-26
CA2741034A1 (en) 2010-04-29
WO2010047767A2 (en) 2010-04-29
JP2012506051A (ja) 2012-03-08
KR20110086074A (ko) 2011-07-27

Similar Documents

Publication Publication Date Title
JP2012506051A (ja) リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム
JP6730410B2 (ja) マルチパラメータ糖尿病リスク評価
JP7861035B2 (ja) 糖尿病への転化を予測する多重マーカリスクパラメータ
US11990243B2 (en) Multiple-marker risk parameters predictive of conversion to diabetes
Braga et al. Biologic variability of C-reactive protein: is the available information reliable?
Beumer Prieto et al. Biological variation of cardiac biomarkers in athletes during an entire sport season
Osredkar et al. Comparison of ADVIA Centaur ultra-sensitive and high-sensitive assays for troponin I in serum
HK40077425A (en) Lipoprotein insulin resistance indexes and related methods, systems and computer program for generating same
Wang et al. Biological variation of cardiovascular biochemical markers in patients with Type 2 Diabetes Mellitus
HK1227097B (en) Multiple-marker risk parameters predictive of conversion to diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121017

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121119

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130918

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131015

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5393798

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250